Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma
暂无分享,去创建一个
B. Seliger | A. Hartmann | C. Stoehr | S. Wach | B. Wullich | Simon Jasinski-Bergner | Michael Friedrich | A. Steven
[1] B. Seliger,et al. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma , 2020, Scientific Reports.
[2] R. Flippot,et al. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma , 2020, Therapeutic advances in medical oncology.
[3] B. Seliger,et al. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy , 2019, Cancer Immunology, Immunotherapy.
[4] M. Hurwitz,et al. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma , 2019, Current Oncology Reports.
[5] Anas M. Saad,et al. Trends in Renal‐Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER‐Based Study , 2019, Clinical genitourinary cancer.
[6] M. Quintanilla,et al. New Insights Into the Role of Qa-2 and HLA-G Non-classical MHC-I Complexes in Malignancy , 2018, Front. Immunol..
[7] A. Lin,et al. Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges , 2018, Front. Immunol..
[8] E. Lam,et al. Renal cell carcinoma: a review of biology and pathophysiology , 2018, F1000Research.
[9] ping wang,et al. Cyclic AMP responsive element-binding protein induces metastatic renal cell carcinoma by mediating the expression of matrix metallopeptidase-2/9 and proteins associated with epithelial-mesenchymal transition. , 2017, Molecular medicine reports.
[10] Charles Swanton,et al. Renal cell carcinoma , 2017, Nature Reviews Disease Primers.
[11] S. Quezada,et al. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer , 2017, The Journal of clinical investigation.
[12] S. George,et al. VEGF inhibitors in renal cell carcinoma. , 2016, Clinical advances in hematology & oncology : H&O.
[13] D. Qian,et al. Systemic Inhibition of CREB is Well-tolerated in vivo , 2016, Scientific Reports.
[14] B. Seliger,et al. HLA-E expression and its clinical relevance in human renal cell carcinoma , 2016, Oncotarget.
[15] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[16] F. Marincola,et al. Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma , 2016, Oncotarget.
[17] M. Terris,et al. Renal cell carcinoma: links and risks , 2016, International journal of nephrology and renovascular disease.
[18] ping wang,et al. Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2 , 2016, Oncotarget.
[19] E. Carosella,et al. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. , 2015, European urology.
[20] B. Seliger,et al. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma , 2015, Oncoimmunology.
[21] V. Pistoia,et al. Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions , 2014, Front. Immunol..
[22] B. Seliger,et al. The role of classical and non-classical HLA class I antigens in human tumors. , 2012, Seminars in cancer biology.
[23] Wong-Ho Chow,et al. Epidemiology and risk factors for kidney cancer , 2010, Nature Reviews Urology.
[24] B. Seliger,et al. Expression and regulation of non-classical HLA-G in renal cell carcinoma. , 2008, Tissue antigens.
[25] W. Leonard,et al. CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation , 2007, The Journal of experimental medicine.
[26] B. Seliger,et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. , 2003, Cancer research.
[27] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[28] P. J. van den Elsen,et al. HLA-G Transactivation by cAMP-response Element-binding Protein (CREB) , 2002, The Journal of Biological Chemistry.
[29] N. Rouas-Freiss,et al. HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.